ClinicalTrials.gg
CompletedNCT04467346Updated Feb 23, 2022

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

A Phase 1 interventional study of Ped-TMZ in Therapeutic Equivalency, sponsored by Orphelia Pharma. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Orphelia Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary objective:

  • Evaluate bioequivalence between Temozolomide Oral Suspension and Temodal® capsules for oral administration.

Secondary objectives:

  • Define the pharmacokinetic parameters of Temozolomide Oral Suspension.
  • Assess the buccal safety of Temozolomide Oral Suspension.
Read the detailed description

The study is an open label, randomized, crossover, 2-period study in 30 male/female patients with primary CNS malignancies. Patients will receive, under fasting conditions, 200 mg/m² of Temozolomide Oral Suspension (Ped-TMZ) or Temodal®, as single oral administration in 2 different study periods depending on the randomization, with no wash out period between administrations.

02

Conditions studied

  • Therapeutic Equivalency
03

In context

Lead sponsor

Orphelia Pharma is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with newly diagnosed glioblastoma multiforme treated with temozolomide (200mg/m2) as monotherapy and patients with recurrent or progressive malignant glioma treated with temozolomide as monotherapy (200mg/m2).
  • Male and female patients at least 18 of age.
  • Non-pregnant, non-breast feeding female.
  • (weight/height²) in the range of 18.5 to 30 kg/m².
  • Having given a written

Exclusion criteria

Exclusion Criteria:

  • Co-administration of sodium valproate
  • Patients with (naso)gastric tubes
  • Patients receiving 150 mg/m² and not eligible to the 200 mg/m² dose
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ped-TMZ

    Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.

    Drug: Ped-TMZ

  • Active comparator
    Temodal capsule

    Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition

    Drug: Ped-TMZ

Interventions

  • Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing

    Also known as: Temozolomide Oral Suspension

06

What researchers measure

Primary outcomes

  1. Primary pharmacokinetic parameter: Cmax

    The Cmax pharmacokinetic parameter will be determined from temozolomide plasma concentrations

    Time frame: Day 1 or Day 2

  2. Primary pharmacokinetic parameter: AUC0-t

    The AUC0-t pharmacokinetic parameter will be determined from temozolomide plasma concentrations

    Time frame: Day 1 or Day 2

Secondary outcomes

  1. Secondary pharmacokinetic parameter: AUC0-inf

    The AUC0-inf pharmacokinetic parameter will be determined from temozolomide plasma concentrations

    Time frame: Day 1 or Day 2

  2. Secondary pharmacokinetic parameter: tmax

    The tmax pharmacokinetic parameter will be determined from temozolomide plasma concentrations

    Time frame: Day 1 and Day 2

  3. Secondary pharmacokinetic parameter: λ

    The λ pharmacokinetic parameter will be determined from temozolomide plasma concentrations

    Time frame: Day 1 and Day 2

  4. Secondary pharmacokinetic parameter: t1/2

    The t1/2 pharmacokinetic parameters will be determined from temozolomide plasma concentrations

    Time frame: Day 1 and Day 2

  5. Secondary pharmacokinetic parameter: residual area

    The residual area of temozolomide will be determined from temozolomide plasma concentrations

    Time frame: Day 1 and Day 2

07

Study locations

3 sites
  • Service de neuro-oncologie - Hospices Civils de Lyon
    Bron, Rhône 69500, France
  • CHU de Bordeaux
    Bordeaux, 33075, France
  • Hôpital de la Timone (AP-HM)
    Marseille, 13005, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2021, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2020
First posted
Jul 13, 2020
StartActual
Sep 25, 2020
Primary completionActual
Dec 17, 2021
CompletionActual
Dec 17, 2021
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04467346
Lead sponsor
Orphelia Pharma
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Sep 25, 2020
Primary completion
Dec 17, 2021
Completion
Dec 17, 2021
Last update
Feb 23, 2022

Study contacts

Caroline Lemarchand, PharmD
study director · Orphelia Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion